# Lysergic Acid Diethylamide (LSD) in Palliative Care

> **NCT05883540** · PHASE2 · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 60 (estimated)

## Conditions studied

- Palliative Care
- Pain
- Anxiety
- Depression
- Demoralization
- Psychological Distress
- Quality of Life
- Caregiver Burden
- Fear of Death
- Existential Distress

## Interventions

- **DRUG:** Lysergic Acid Diethylamide Tartrate
- **DRUG:** Lysergic Acid Diethylamide Tartrate

## Key facts

- **NCT ID:** NCT05883540
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-09
- **Primary completion:** 2027-09
- **Final completion:** 2028-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05883540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05883540, "Lysergic Acid Diethylamide (LSD) in Palliative Care". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05883540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*